Doylestown, Pennsylvania — According to state and local development sources, Apozeal Pharmaceuticals plans to invest $4,100,000.00 to expand in Doylestown. The company plans to occupy the new space in Doylestown, on or about April 1, 2026. According to the company website Apozeal Pharmaceuticals Inc. is a pharmaceutical company dedicated to developing and manufacturing high-quality medicines with a focus on affordability and integrity. Founded in 2023 by experienced pharmaceutical executives, the company currently owns ten FDA-approved ANDA products for the U.S. market, with many more pending approval and in development. Apozeal Pharmaceuticals offers a range of services including research and development, analytical testing, manufacturing of oral liquid solutions, suspensions, and suppositories, as well as packaging and contract development (CDMO). Their facility in Levittown, PA, is equipped for cGMP manufacturing and packaging with serialization capabilities. Recently, Apozeal announced the U.S. market launch of its first product, Hydroxyzine HCL Solution, USP 10mg/5ml, manufactured at their Pennsylvania facility, and plans to introduce nine additional FDA-approved products soon.

To learn more about Apozeal Pharmaceuticals, visit https://apozealpharma.com/

Company Contact:
Sadath Shareef, Chief Executive Officer
215-949-0809

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.